Ascendis Pharma A/S

Ascendis Pharma A/S EBIT

The EBIT of Ascendis Pharma A/S (ASND) as of Nov 20, 2026 is -130.89 M EUR. In the previous year, EBIT was -278.76 M EUR — a change of -53.05% (higher).

EBIT

-130.89 MEUR

YoY

-53.05%

Last updated:

In 2025, Ascendis Pharma A/S's EBIT was -130.89 M EUR, a -53.05% increase from the -278.76 M EUR EBIT recorded in the previous year.

The Ascendis Pharma A/S EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
-455.54 M EUR
Jan 1, 2024
-278.76 M EUR
Jan 1, 2025
-130.89 M EUR
Jan 1, 2026 (e)
1.23 B EUR
Jan 1, 2027 (e)
867.24 M EUR
Jan 1, 2028 (e)
1.18 B EUR
Jan 1, 2029 (e)
1.44 B EUR
Jan 1, 2030 (e)
1.69 B EUR
The Ascendis Pharma A/S EBIT history
YEAREBITYoY
est1.69 BEUR+17.13%
est1.44 BEUR+22.21%
est1.18 BEUR+36.09%
est867.24 MEUR-29.25%
est1.23 BEUR-1,036.52%
-130.89 MEUR-53.05%
-278.76 MEUR-38.81%
-455.54 MEUR-18.92%
-561.81 MEUR+24.35%
-451.79 MEUR+36.65%
-330.62 MEUR+45.83%
-226.72 MEUR+46.50%
-154.76 MEUR+38.74%
-111.54 MEUR+52.96%
-72.92 MEUR+74.35%
-41.83 MEUR+248.86%
-11.99 MEUR-327.11%
5.28 MEUR+248.91%
1.51 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ascendis Pharma A/S Revenue

Ascendis Pharma A/S Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
266.72 M EUR
-455.54 M EUR
-481.45 M EUR
Jan 1, 2024
363.64 M EUR
-278.76 M EUR
-378.08 M EUR
Jan 1, 2025
691.71 M EUR
-130.89 M EUR
-219.03 M EUR
Jan 1, 2026 (e)
1.38 B EUR
1.23 B EUR
897.79 M EUR
Jan 1, 2027 (e)
2.02 B EUR
867.24 M EUR
605.52 M EUR
Jan 1, 2028 (e)
2.52 B EUR
1.18 B EUR
909.53 M EUR
Jan 1, 2029 (e)
3.01 B EUR
1.44 B EUR
1.11 B EUR
Jan 1, 2030 (e)
3.41 B EUR
1.69 B EUR
1.31 B EUR

Ascendis Pharma A/S Margins

Ascendis Pharma A/S stock margins

The Ascendis Pharma A/S margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ascendis Pharma A/S. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ascendis Pharma A/S.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
83.36 %
-170.80 %
-180.51 %
Jan 1, 2024
87.83 %
-76.66 %
-103.97 %
Jan 1, 2025
85.08 %
-18.92 %
-31.67 %
Jan 1, 2026 (e)
85.08 %
88.87 %
65.08 %
Jan 1, 2027 (e)
85.08 %
42.91 %
29.96 %
Jan 1, 2028 (e)
85.08 %
46.80 %
36.07 %
Jan 1, 2029 (e)
85.08 %
47.92 %
37.04 %
Jan 1, 2030 (e)
85.08 %
49.50 %
38.52 %

Ascendis Pharma A/S Stock analysis

What does Ascendis Pharma A/S do? Ascendis Pharma A/S is a biopharmaceutical company based in Denmark that focuses on developing innovative therapies for diseases that currently have no suitable treatment options. The company was founded in 2007 and is headquartered in Hellerup, Denmark. History The company was founded by an experienced team of researchers and professionals from the pharmaceutical and biotech industry who recognized the need for new therapies for chronic diseases. They used innovative technologies to develop drugs that would have longer-lasting effects, thus reducing the need for frequent doses. In 2015, the company went public to raise additional capital for the further development of their technologies and products. Business model Ascendis Pharma A/S is working on the development of drugs using a proprietary technology platform called TransCon technology. TransCon technology is a novel delivery system that allows drugs to remain in the body for longer periods of time, thus achieving a continuous effect. This leads to a reduced need for frequent doses, improving patient care and adherence to therapy. The company follows an asset-based business model strategy. It aims to market its products globally through a licensing and partnering approach. By partnering with established pharmaceutical companies, Ascendis Pharma A/S can introduce their drugs into broader markets while ensuring resources for further research and development. Divisions Ascendis Pharma A/S has two main business divisions: 1. Endocrinology: Ascendis Pharma A/S is a leader in the development of therapies for diseases caused by hormonal disorders. The TransCon technology is used for the delivery of hormones such as growth hormone, parathyroid hormone, follicle-stimulating hormone, and luteinizing hormone to achieve continuous release in the body. 2. Oncology: The company also utilizes the TransCon technology for the delivery of cytokines for cancer immunotherapy. Products The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone, a growth hormone therapy that has longer-lasting effects and only needs to be administered once a week for children with growth hormone deficiency. The company also has TransCon PTH and TransCon CNP in the endocrinology pipeline. In oncology, the company has developed TransCon IL-2, an interleukin-2 immunotherapy for cancer. Summary Ascendis Pharma A/S is an innovative biopharmaceutical company specializing in the development of therapies for chronic diseases. The company utilizes its proprietary technology platform, TransCon technology, to develop drugs that have longer-lasting effects and reduce the need for frequent doses. It focuses on endocrinology and oncology and follows an asset-based business model strategy by entering partnerships with established pharmaceutical companies. The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone. Ascendis Pharma A/S is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Ascendis Pharma A/S's EBIT

Ascendis Pharma A/S's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Ascendis Pharma A/S's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Ascendis Pharma A/S's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Ascendis Pharma A/S’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Ascendis Pharma A/S stock

EBIT of Ascendis Pharma A/S is -130.89 M EUR in 2025.

EBIT of Ascendis Pharma A/S changed from -278.76 M EUR to -130.89 M EUR, representing a -53.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Ascendis Pharma A/S since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Ascendis Pharma A/S historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Ascendis Pharma A/S

All Key Metrics — Ascendis Pharma A/S